Global Car T Cell Therapy Market Research Report Forecast to 2027

List of Tables

CAR-T Cell Therapy Market Forecast till 2027

Market Overview

The growing market trends and demand are expected to have a positive impact on the market size of CAR-T cell therapy products. CAR-T cell therapy, using re-engineered patient WBCs to identify and combat cancer cells, is a cutting-edge treatment method. CAR-T cell therapy consists of using modified T cells to target and eliminate cancer cells. It consists of three phases: collecting T cells, engineering them, and infusing them into the patient's body. CAR-T cell therapy harnesses the body's immune system to combat cancer. However, cytokine release syndrome (CRS) can occur as a side effect, causing symptoms like fever, fatigue, nausea, low blood pressure, breathing difficulties, and more.

The CAR T therapy industry is expected to experience strong growth in the coming years due to a rising number of cancer cases worldwide. The treatment has gained widespread interest due to its remarkable results and has received approval from the FDA for two treatments in 2017. The growth of the life science and biotechnology sectors, coupled with increasing patient assistance programs and government efforts to raise cancer awareness, will further support the industry's expansion.

Segment Overview

The CAR-T cell therapy market is segmented based on targeted antigens, including BCMA, CD19/CD22, Lewis Y, PSCA, NKR-2, MUC16, ROR1, and others.

Acute Lymphoblastic Leukemia and Diffuse Large B-cell Lymphoma are the primary applications of CAR-T cell therapy, with the Acute Lymphoblastic Leukemia segment expected to see the fastest growth due to heightened awareness of its use in treating acute leukemia and the expected launch of drugs to treat blood cell cancer. The segment's growth will be further driven by an increase in cases of Acute Lymphoblastic Leukemia and support from both public and private organizations.

Regional Analysis

North America leads the CAR-T market since the region has high presence of many life sciences companies working on CAR T-cell development and distribution, as well as advanced quality control systems.

The Asia Pacific CAR-T therapy market is projected to grow rapidly, attributed to rising awareness, improved healthcare infrastructure, developing business and commercial centers, and increased company investments. Government support through funding and regulations also contributes to growth, such as South Korea passing a law in 2020 to ensure patient safety during clinical trials and strengthen support for regenerative medicine.

Major Players

Key players in the market Cellectis (France), Caribou Biosciences, Inc. (US), Bluebird Bio (US), Noile-Immune Biotech (Japan), Celyad (Belgium), Celgene Corporation (US), Bellicum Pharmaceuticals, Inc. (US), Intellia Therapeutics (US), Novartis International AG (Swiss), Pfizer Inc. (US), Servier Laboratories (France), Mereck KGaA (Germany), and Amgen Inc. (US).

COVID 19 Impacts

The COVID-19 pandemic has had a great impact on the global economy since its emergence in late 2019. The World Health Organization declared it a global health crisis in 2020. The virus has affected the availability of drugs and vaccines, created disruptions in their distribution, and had financial consequences for companies and financial markets. Nationwide lockdowns hindered the transportation of drugs and vaccines in countries such as Saudi Arabia, India, U.A.E., China, and Egypt. The World Health Organization reported that as of November 15, 2022, there were over 632 million confirmed cases of COVID-19 worldwide.

The pandemic also has significant implications for cancer patients receiving CAR-T cell therapy. For example, data published by Duke-NUS, a school of National University of Singapore, in April 2020 indicated that CAR-T cell therapy may be useful for treating SARS-CoV-2 and other infectious diseases.

Product Code: MRFR/HC/6630-CR

1 EXECUTIVE SUMMARY

1.1 OVERVIEW 11
- 1.1.1 MARKET SYNOPSIS 11

2 MARKET INTRODUCTION

2.1 DEFINITION 12
2.2 SCOPE OF THE STUDY 12
2.3 RESEARCH OBJECTIVE 12
2.4 LIST OF ASSUMPTIONS & LIMITATIONS 13

3 RESEARCH METHODOLOGY

3.1 DATA MINING 14
3.2 SECONDARY RESEARCH 15
3.3 PRIMARY RESEARCH 16
- 3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 16
- 3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS 17
3.4 FORECASTING TECHNIQUES 18
3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 19
- 3.5.1 BOTTOM-UP APPROACH 20
- 3.5.2 TOP-DOWN APPROACH 20
3.6 DATA TRIANGULATION 21
3.7 VALIDATION 21

4 MARKET DYNAMICS

4.1 OVERVIEW 22
4.2 DRIVERS 23
- 4.2.1 INCREASING PREVALENCE OF CANCER ACROSS THE GLOBE 23
- 4.2.2 TECHNOLOGICAL ADVANCEMENTS IN THE TREATMENT THERAPIES FOR CANCER 23
- 4.2.3 GROWING PHARMACEUTICAL INDUSTRY 23
- 4.2.4 INCREASE IN THE NUMBER OF CLINICAL STUDIES FOR CELL THERAPY 24
4.3 RESTRAINTS 25
- 4.3.1 SIDE EFFECTS OF CAR T-CELL THERAPY 25
- 4.3.2 HIGH COST OF TREATMENT 25
4.4 OPPORTUNITY 26
- 4.4.1 INVESTIGATION ON CAR-T THERAPY FOR THE TREATMENT OF SEVERAL HEMATOLOGIC AND SOLID

TUMOR TYPES 26

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES ANALYSIS 27
- 5.1.1 THREAT OF NEW ENTRANTS 27
- 5.1.2 BARGAINING POWER OF SUPPLIERS 28
- 5.1.3 BARGAINING POWER OF BUYERS 28
- 5.1.4 THREAT OF SUBSTITUTES 28
- 5.1.5 INTENSITY OF RIVALRY 28
5.2 CLINICAL TRIALS ANALYSIS 29
5.3 COVID-19 IMPACT ANALYSIS 36
- 5.3.1 IMPACT ON GDP GROWTH 36
- 5.3.2 IMPACT ON SUPPLY CHAIN 37
- 5.3.3 IMPACT ON PRODUCTION 37
- 5.3.4 IMPACT ON KEY PLAYERS 37

6 GLOBAL CAR T CELL THERAPY MARKET, BY TARGET ANTIGEN

6.1 OVERVIEW 38
- 6.1.1 CD19 39
- 6.1.2 CD22 40
- 6.1.3 OTHERS 40

7 GLOBAL CAR T CELL THERAPY MARKET, BY APPLICATION

7.1 OVERVIEW 41
- 7.1.1 DIFFUSE LARGE B-CELL LYMPHOMA 43
- 7.1.2 ACUTE LYMPHOBLASTIC LEUKEMIA 44
- 7.1.3 OTHERS 44

8 GLOBAL CAR T CELL THERAPY MARKET, BY REGION

8.1 OVERVIEW 45
8.2 US 46
8.3 EUROPE 48
8.4 CHINA 49
8.5 REST OF THE WORLD (ROW) 50

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW 51
9.2 MAJOR PLAYERS IN THE GLOBAL CAR T CELL THERAPY MARKET 51
9.3 COMPETITIVE BENCHMARKING 52
9.4 COMPETITOR DASHBOARD 53
9.5 DEVELOPMENTS IN THE GLOBAL CAR TCELL THERAPY MARKET 53
- 9.5.1 ACQUISITION 53
- 9.5.2 JOINT VENTURES 54
- 9.5.3 EXPANSION 55
- 9.5.4 REGULATORY APPROVALS 56
- 9.5.5 IND CLEARANCES 56
- 9.5.6 PRODUCT LAUNCH/PRODUCT APPROVAL 57

10 COMPANY PROFILES

10.1 NOVARTIS AG 58
- 10.1.1 COMPANY OVERVIEW 58
- 10.1.2 FINANCIAL OVERVIEW 58
- 10.1.3 PRODUCTS/SERVICES OFFERED 59
- 10.1.4 KEY DEVELOPMENTS 59
- 10.1.5 SWOT ANALYSIS 60
- 10.1.6 KEY STRATEGIES 60
10.2 PFIZER, INC. 61
- 10.2.1 COMPANY OVERVIEW 61
- 10.2.2 FINANCIAL OVERVIEW 61
- 10.2.3 PRODUCTS/SERVICES OFFERED 62
- 10.2.4 KEY DEVELOPMENTS 62
- 10.2.5 SWOT ANALYSIS 63
- 10.2.6 KEY STRATEGIES 63
10.3 KITE PHARMA 64
- 10.3.1 COMPANY OVERVIEW 64
- 10.3.2 FINANCIAL OVERVIEW 64
- 10.3.3 PRODUCTS/SERVICES OFFERED 65
- 10.3.4 KEY DEVELOPMENTS 65
- 10.3.5 SWOT ANALYSIS 66
- 10.3.6 KEY STRATEGIES 66
10.4 CELLECTIS 67
- 10.4.1 COMPANY OVERVIEW 67
- 10.4.2 FINANCIAL OVERVIEW 67
- 10.4.3 PRODUCTS/SERVICES OFFERED 68
- 10.4.4 KEY DEVELOPMENTS 68
- 10.4.5 SWOT ANALYSIS 69
- 10.4.6 KEY STRATEGIES 69
10.5 AUTOLUS THERAPEUTICS PLC 70
- 10.5.1 COMPANY OVERVIEW 70
- 10.5.2 FINANCIAL OVERVIEW 70
- 10.5.3 PRODUCTS/SERVICES OFFERED 70
- 10.5.4 KEY DEVELOPMENTS 71
- 10.5.5 SWOT ANALYSIS 71
- 10.5.6 KEY STRATEGIES 71
10.6 CARSGEN THERAPEUTICS 72
- 10.6.1 COMPANY OVERVIEW 72
- 10.6.2 FINANCIAL OVERVIEW 72
- 10.6.3 PRODUCTS/SERVICES OFFERED 72
- 10.6.4 KEY DEVELOPMENTS 72
- 10.6.5 SWOT ANALYSIS 73
- 10.6.6 KEY STRATEGIES 73
10.7 JUNO THERAPEUTICS 74
- 10.7.1 COMPANY OVERVIEW 74
- 10.7.2 FINANCIAL OVERVIEW 74
- 10.7.3 PRODUCTS/SERVICES OFFERED 75
- 10.7.4 KEY DEVELOPMENTS 75
- 10.7.5 SWOT ANALYSIS 75
- 10.7.6 KEY STRATEGIES 76
10.8 SORRENTO THERAPEUTICS, INC. 77
- 10.8.1 COMPANY OVERVIEW 77
- 10.8.2 FINANCIAL OVERVIEW 77
- 10.8.3 PRODUCTS OFFERING 77
- 10.8.4 KEY DEVELOPMENTS 78
- 10.8.5 SWOT ANALYSIS 78
- 10.8.6 KEY STRATEGY 78
10.9 LEGEND BIOTECH 79
- 10.9.1 COMPANY OVERVIEW 79
- 10.9.2 FINANCIAL OVERVIEW 79
- 10.9.3 PRODUCTS/SERVICES OFFERED 80
- 10.9.4 KEY DEVELOPMENTS 80
- 10.9.5 SWOT ANALYSIS 81
- 10.9.6 KEY STRATEGIES 81
10.10 MUSTANG BIO 82
- 10.10.1 COMPANY OVERVIEW 82
- 10.10.2 FINANCIAL OVERVIEW 82
- 10.10.3 PRODUCTS/SERVICES OFFERED 83
- 10.10.4 KEY DEVELOPMENTS 83
- 10.10.5 SWOT ANALYSIS 84
- 10.10.6 KEY STRATEGIES 84

11 APPENDIX

11.1 REFERENCES 85
11.2 RELATED REPORTS 85